Global Down Syndrome

Summer 2018

Issue link: https://viewer.e-digitaledition.com/i/1038839

Contents of this Issue

Navigation

Page 9 of 31

SCIENCE SNPs WATCHING OUT FOR THE LIVER A study of 280 Italian children with Down syndrome revealed a significantly increased prevalence, relative to the typical pediatric population, of a condition known as nonalcoholic fatty liver disease (NAFLD). In NAFLD, which is considered the most chronic liver disease worldwide, excessive fat accumulates in the liver, potentially leading to liver scarring, or fibrosis. In typical people, NAFLD is often associated with obesity and physical inactivity. However, researchers observed a high prevalence of NAFLD among lean children with Down syndrome, suggesting a different cause for the abnormal accumulation of liver fat. Further investigation revealed that children with Down syndrome displayed elevated levels of adipocytokines, a group of inflammatory proteins involved in the development of NAFLD. Thus, scientists concluded that NAFLD in Down syndrome is likely caused by systemic inflammation, even in the absence of obesity. These results justify further investigations to define whether NAFLD can progress into fibrosis among those with trisomy 21 and whether anti-inflammatory strategies could improve liver function in this population. Valentini, et al. The Journal of Pediatrics. 2017; 189:92–97. LATEST EPIDEMIOLOGY OF ALZHEIMER'S DISEASE IN DOWN SYNDROME The largest epidemiological study of Alzheimer's disease in people with Down syndrome to date was recently published by a group of scientists in England. The study is rich with observations about Alzheimer's disease onset and progression in this population. According to the report, the mean age of dementia diagnosis for a person with Down syndrome is 55.8, with a mean survival of 3.78 years after diagnosis. However, the age of dementia diagnosis varies greatly, ranging from the mid- 30s to mid-70s. Men tend to be diagnosed later than women, but women live longer than men after diagnosis. History of epilepsy was found to be a risk factor for lower survival rates after diagnosis, while depression, sensory impairment, and hypothyroidism were not. Those living with their families at the time of diagnosis lived longer than those living independently or in residential settings. Finally, people with Down syndrome who took the Alzheimer's disease medications acetylcholinesterase inhibitors and memantine lived longer after diagnosis. Altogether, these results provide a strong foundation for future studies of risk factors and interventions for Alzheimer's disease in people with Down syndrome. Sinai, et al. Journal of Alzheimer's Disease. 2018; 61(2):717-728. (about 10 percent, which is significantly higher than in the general population), gastrointestinal malformations (12 percent), thyroid disease (4–18 percent), leukemia (1 percent), and other autoimmune disorders including celiac disease (5 percent). However, people with Down syndrome infrequently develop solid tumor cancers, such as breast or prostate cancer, and despite multiple risk factors for coronary artery disease and high rates of obesity, sleep apnea, and Type 1 diabetes, they rarely develop atherosclerosis or have myocardial infarctions. Furthermore, despite increases in lifespan among individuals with Down syndrome, opportunities for them to participate in medication trials have been limited. ... Experience from NICHD's "DS-Connect®: The Down Syndrome Registry" suggests that there is great interest in participating in clinical studies. RESEARCH FOR HEALTH IN DOWN SYNDROME AND CO-OCCURRING CONDITIONS ... INCLUDE will build a comprehensive, trans-NIH strategy to address critical health and quality-of-life needs for individuals with Down syndrome, leveraging the full range of resources across NIH to bring results rapidly to individuals with Down syndrome and their families. The main goals are to accelerate the development of new therapies, while simultaneously bringing promising agents already in development to individuals with Down syndrome as quickly as possible. At the same time, full inclusion of individuals with Down syndrome into ongoing clinical trials will ensure that they will reap the benefits of agents already in development. ... This effort will appropriately take advantage of … the expertise of at least 18 NIH institutes and centers, including the NCI, NIA, National Institute of Allergy and Infectious Diseases, NICHD, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Mental Health, National Institute of Neurological Disorders and Stroke, National Institute on Minority Health and Health Disparities, and the National Center for Complementary and Integrative Health. A comprehensive clinical cohort study with deep phenotyping and exploration of pan-'omics (e.g. genomics, transcriptomics) would permit identification of biomarkers and outcomes for the co-occurring conditions in Down syndrome. Coupled with development of a clinical trials readiness program, and informed by basic science discoveries, this combination of resources could have a great impact on addressing health disparities that exist for people with Down syndrome and could also lead to the development of therapies to improve outcomes for those with and without the condition. Therefore, INCLUDE will have three major components: • Component 1: Targeted, high risk–high reward, basic science studies CONTINUED FROM PAGE 10 2018 ISSUE 3 OF 4 • DOWN SYNDROME WORLD ™ 10

Articles in this issue

Archives of this issue

view archives of Global Down Syndrome - Summer 2018